

October 30, 2018

Partnerships for Vaccines Forum

PATH's 40+ years of transformative innovation


Steve Davis
President & CEO, PATH






PATH is a global team of innovators working to eliminate health inequities so people, communities, and economies can thrive.

Today, we are a global team of 1,500+, working in 70+ countries.







PATH VACCINES

PATH VACCINES - Center for Vaccine Innovation & Access (CVIA)

**Pre-clinical & Clinical
Strategies, Partnerships
& Support**


**Introduction Design
& Studies**

**Vaccine Development
Partnerships Across
Value Chain, Including
PQ Support**

**Immunization Data and
Digital Tools**

**Delivery & Cold Chain
Tools**


**Policy, Advocacy, Market
Shaping and Support**



PDP - Product Development Partnership

A unique, non-profit business model bringing together public, private, academic and philanthropic sectors to develop technologies for global health. PDPs pave the way for new research on infectious diseases and accelerate the development of safe and effective vaccines, drugs and diagnostics for the most vulnerable populations as quickly and cheaply as possible.

- Sharing the risk
- Sharing the cost



PATH CVIA in action



Priming a local manufacturer to fill a critical market gap

PATH helped Bharat Biotech of India build the technical capacity to produce a high-quality, low-cost rotavirus vaccine. ROTAVAC® is a success story for improving affordable vaccine supply and tackling diarrhea in India and around the world.



Developing and introducing a vaccine in record time


In partnership with the WHO and Serum Institute of India, PATH helped develop and deliver MenAfriVac®, a vaccine developed specifically for Africa. The vaccine has virtually eliminated group A meningitis wherever it's been introduced.



Improving supply and accessibility for polio eradication

PATH provided technical assistance to Beijing Bio-Institute Biological Products in the key, early stages of WHO prequalification for its new bivalent oral polio vaccine. The vaccine will meet increased demand during this critical phase of polio eradication.

PATH Vaccines portfolio* includes over two dozen vaccines in development and use across 17 disease targets



* Portfolio snapshot current as of June 2018; does not include new/ongoing proposal development work in dengue, Zika, or Ebola, nor ongoing support to the Expanded Programme on Immunization in multiple countries.

All of our work is built on trusted partnerships



MNCs &
Research
Centers



Public &
Private
Funders



Developing
Country
Manufacturers



Other
PDPs &
NGOs



New Partners:
MRI, CEPI &
Others

A 15-year, multi-sector
partnership became a
turning point in the
battle to protect
children against
Japanese Encephalitis


A brief introduction to Japanese encephalitis



Photos: (clockwise from left) PATH/Aaron Joel Santos, PATH/Rocky Prajapati, PATH/Rocky Prajapati, PATH/Rocky Prajapati, PATH/Rocky Prajapati

A historic moment.

WHO prequalification of CDIBP's JE vaccine signaled China's emergence in the global vaccine marketplace.





Over the past 15 years, PATH has worked with Japanese encephalitis-endemic countries to introduce and expand JE immunization programs, reaching around 300 million people.


- PATH supported JE vaccine introduction or expansion
- PATH is providing additional support to further JE control

300
million

Children vaccinated against JE



“Mind the gap”: A second “valley of death”?



Second Valley of Death – Implementation Gap

